SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its identity as a culture-focused crypto, with sentiment buoyed by recent legal developments in the hemp industry and ongoing anticipation for upcoming 4/20 festivities. Holders are emphasizing the project's long-term, organic growth strategy and its role as a digital extension of global cannabis culture, setting it apart from typical hype-driven assets.

Maulcoin

Maulcoin is surging in community discussions as supporters rally behind recent ticker recovery and growing organic engagement. The community is actively pushing for a breakout, focusing on upcoming milestones and potential airdrops as they aim to establish the project within the broader meme coin ecosystem.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is trending due to anticipation surrounding a major cross-chain event and positive sentiment regarding its role as the primary liquidity hub for the Base ecosystem. Investors are actively discussing the protocol's revenue growth, the impact of recent tokenomics shifts, and bullish outlooks as they track potential price action ahead of industry conferences.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is currently trending as it faces significant downward pressure from institutional de-risking and market fears that AI models could disrupt established enterprise software workflows. While retail investors remain sharply divided between those calling for a structural collapse and those viewing the current valuation as a deep-value opportunity, the ongoing debate centers on whether Jiras operational moat can withstand the rapid integration of AI-driven alternatives.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF is seeing heavy volatility as investors debate whether AI models like Anthropic's represent an existential threat to traditional SaaS or a platform for new efficiency gains. While the sector has faced aggressive sell-offs and valuation resets, community members remain sharply divided on whether current levels offer a generational buying opportunity or signal a deeper structural collapse in enterprise software.

WorldFinancial

WorldFinancial (WLFI) is currently trending amid significant volatility and intense scrutiny surrounding its foreign investment deals and government probes. While some community members view recent price action as a manipulative accumulation phase ahead of upcoming industry forums, others express deep skepticism, labeling the project as a speculative high-risk venture characterized by concerns over insider lockups and transparency.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors react to a significant earnings miss and the company's first quarterly report under new CEO Greg Abel, which featured a sharp decline in insurance profits and no immediate share buybacks. The community remains deeply divided, with some critics labeling the conglomerate 'dead money' due to its massive cash pile and lack of growth, while bullish long-term holders argue that the recent sell-off provides a strategic entry point for a firm with unmatched balance sheet strength.

Wells Fargo & Co. is a diversified and community-based financial services company, which engages in the provision of banking, insurance, investments, mortgage, and consumer and commercial finance products and services. It operates through the following segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. The Consumer Banking and Lending segment offers consumer and small business banking, home lending, credit cards, auto, and personal lending. The Commercial Banking segment provides banking and credit products across industry sectors and municipalities, secured lending and lease products, and treasury management. The Corporate and Investment Banking segment is composed of corporate banking, investment banking, treasury management, commercial real estate lending and servicing, and equity and fixed income solutions, as well as sales, trading, and research capabilities. The Wealth and Investment Management segment refers to personalized wealth management, brokerage, financial planning, lending, private banking, trust, and fiduciary products and services. The company was founded by Henry Wells and William G. Fargo on March 18, 1852 and is headquartered in San Francisco, CA.

Wells Fargo & Co.

Wells Fargo is in focus as investors analyze the bank's latest earnings report, which highlighted solid net interest income and fee growth alongside strategic cost-cutting efforts. The market is also actively weighing the impact of the bank's recently lifted asset cap and its ongoing push into new sectors like options clearing, while some community members remain wary of legal settlements and the bank's historical regulatory challenges.

Sei is a high-performance Layer 1 blockchain that scales the EVM with parallelized execution, enabling faster transactions, low fees, and seamless smart contract deployment. Sei removes traditional blockchain bottlenecks while maintaining full Ethereum compatibility. The upcoming Giga upgrade will deliver 50x improvements in EVM throughput, optimizing execution, consensus, and storage to push blockchain performance to web2 levels.

Sei is experiencing renewed community focus as investors track its potential as a high-performance Layer-1 blockchain, with active discussions centering on upcoming network upgrades and its growing role in real-world asset tokenization. Traders are debating the project's long-term utility versus its recent price volatility, while many remain optimistic about its capacity to capture institutional interest and scale within the DeFi ecosystem.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma (XPL) is currently experiencing intense volatility and polarizing community sentiment following its recent exchange listings, with investors fiercely debating whether the token is a high-utility stablecoin infrastructure play or a speculative pump-and-dump scheme. The conversation is dominated by contrasting perspectives as some traders focus on potential price recovery and technical breakouts, while others express significant frustration over consistent downward pressure and perceived team inactivity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

<ul class="summary-bullets"><li>The Gilead-Tubulis deal is aimed at expanding Gilead’s ADC capabilities by adding Tubulis’s assets that include its lead asset TUB-040.</li><li>According to Leerink analyst Andrew Berens, this acquisition serves as further validation of the antibody-drug conjugate space including Sutro Biopharma.&nbsp;</li><li>Leerink believes Sutro represents a similar set-up as Tubulis, although earlier in clinical development and technological validation.</li></ul><p>Gilead Sciences, Inc. (GILD) said on Tuesday that it has entered into a definitive agreement to acquire a private German clinical-stage biotechnology company, Tubulis GmbH, a move that investment bank Leerink believes should be a tailwind for other antibody-drug conjugate (ADC) platform companies like Sutro Biopharma.</p><p>STRO shares rose 7% at the time of writing while GILD fell 1%.</p><h2 class="st-heading-2">Gilead-Tubulis Agreement Terms</h2><p>Under the terms of the deal, Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash consideration, and up to $1.85 billion in contingent milestone payments.</p><p>The move is aimed at expanding Gilead’s Antibody-drug conjugates capabilities by adding Tubulis’s assets, including its lead asset TUB-040 which is in development to treat certain ovarian cancer and non-small cell lung cancer patients.</p><p>The transaction is expected to close in the second quarter of 2026, Gilead said.</p><p>ADCs are targeted biopharmaceutical cancer treatments that deliver potent cancer drugs directly to cancer cells while minimizing healthy tissue damage.</p><h2 class="st-heading-2">Leerink Weighs In</h2><p>According to Leerink analyst Andrew Berens, this acquisition serves as further validation of the ADC space and should be a tailwind for other ADC platform companies ,including Sutro Biopharma (STRO), as well as Immunome (IMNM) and Zymeworks (ZYME). This deal underscores the strategic value of an ADC discovery platform anchored to a lead asset to large pharma, Berens said.</p><p>However, while there are a number of similarities between Tubulis' platform and portfolio and that of Sutro, it is possible the acquisition price may have been supported by potential expansion of the Tubulis chemistry and technology beyond oncology and into inflammation and virology, Leerink said, as per TheFly. Leerink believes Sutro represents a similar set-up, although earlier in clinical development and technological validation.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around GILD stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume &nbsp;stayed at ‘high’ levels.</p><p>Meanwhile, sentiment around STRO stock remained ‘bullish,’ coupled with ‘low’ message volume.</p><p>While <a href="https://stocktwits.com/symbol/GILD">GILD shares</a> have risen 31% this year, <a href="https://stocktwits.com/symbol/STRO">STRO stock</a> has nearly quadrupled.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-launches-higher-dose-of-wegovy-injection-across-us/cZJJyAuRIpU">Novo Nordisk Launches Higher Dose Of Wegovy Injection Across US — Retail Thinks Stock Is ‘Terribly Undervalued’</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Gilead-Tubulis $5B Deal Gives STRO Stock A Boost — Here’s Why

Gilead said earlier on Tuesday that it will acquire Tubulis for up to $5 billion. 

Equity

Gilead said earlier on Tuesday that it will acquire Tubulis for up to $5 billion. 



Sutro Biopharma (NASDAQ:STRO) Coverage Initiated by Analysts at Leerink Partners

Leerink Partners initiated coverage on shares of Sutro Biopharma in a report on Tuesday. They set an "outperform" rating and a $38.00 price objective for the company...

Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised Sutro Biopharma from a "sell" rating to a "hold" rating in a report on Saturday...

HC Wainwright Lowers Earnings Estimates for Sutro Biopharma

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for Sutro Biopharma in a report issued on Tuesday, March 24th. HC...

Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Sutro Biopharma (NASDAQ:STRO) Stock Price

Deutsche Bank Aktiengesellschaft upped their target price on shares of Sutro Biopharma from $51.00 to $55.00 and gave the stock a "buy" rating in a research report on Wednesday...

HC Wainwright Predicts Sutro Biopharma FY2030 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Investment analysts at HC Wainwright issued their FY2030 EPS estimates for Sutro Biopharma in a report issued on Tuesday, March 24th. HC Wainwright...

Sutro Biopharma (NASDAQ:STRO) Raised to "Overweight" at Wells Fargo & Company

Wells Fargo & Company upgraded Sutro Biopharma from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $8.00 to $27.00 in a research note on Tuesday...

Sutro Biopharma (NASDAQ:STRO) Raised to Buy at HC Wainwright

HC Wainwright raised Sutro Biopharma from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $10.00 to $28.00 in a research report on Tuesday...

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$2.63	--	--	N/A
Q4 '25	-$8.16	-$5.29	35.19%	BEAT
Q3 '25	-$0.39	-$6.70	-1598.54%	MISSED
Q2 '25	-$0.38	-$0.14	63.39%	BEAT
Q1 '25	-$0.64	-$0.91	-41.62%	MISSED

STRO
Sutro Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest STRO News

STROSutro Biopharma Inc